Shares of Hims & Hers (NYSE: HIMS) have been all over the map over the past few months as GLP-1s have gone from tailwind to headwind for the company's growth. But the bigger picture tells us that ...

Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Thursday in possible sympathy with Eli Lilly And Co’s (NYSE:LLY), ...

Stocks were lower Thursday as traders weighed a greater-than-expected increase in weekly jobless claims and awaited the U.S.

On Wednesday, Hims & Hers Health Inc (HIMS) stock saw a decline, ending the day at $22.36 which represents a decrease of $-0.44 or -1.93% from the prior close of $22.8. The stock opened at $22.64 and ...

Hims & Hers shares gained Monday after the Food and Drug Administration said compounding pharmacies could continue to produce copycat weight-loss drugs while it reconsiders whether there is a ...

Leerink Partners analyst Michael Cherny has maintained their neutral stance on HIMS stock, giving a Hold rating yesterday. Michael ...

BofA Securities adjusted its outlook on Hims and Hers (NYSE:HIMS), raising the price target to $23.00 from $20.00 and maintaining a Buy rating. The revision follows the U.S. Food and Drug ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...

On Wednesday, Truist Securities maintained its Hold rating on Hims & Hers Health, Inc. (NYSE:HIMS) stock with a price target of $23.00. The firm's stance comes amidst recent volatility in the ...

BofA Securities adjusted its outlook on Hims and Hers (NYSE:HIMS), raising the price target to $23.00 from $20.00 and maintaining a Buy rating. The revision follows the U.S. Food and Drug ...